Generic Name and Formulations:
Cyproheptadine HCl 4mg; scored tabs.
Various generic manufacturers
Indications for Cyproheptadine:
Allergic and vasomotor rhinitis, conjunctivitis, urticaria, angioedema, reactions to blood. Adjunct in anaphylaxis. Cold urticaria. Dermatographism.
≥14yrs: initially 4mg 3 times daily; usual range 12–16mg/day; max 0.5mg/kg per day.
<2yrs: not recommended. 2–6yrs: 2mg 2–3 times per day; max 12mg daily. 7–14yrs: 4mg 2–3 times per day; max 16mg daily.
MAOIs. Glaucoma. GI or urinary obstruction. Elderly. Debilitated. Neonates. Premature infants. Nursing mothers.
Hyperthyroidism. Cardiovascular disease. Hypertension. Increased intraocular pressure. History of asthma. Pregnancy (Cat.B).
See Contraindications. Anticholinergic effects potentiated by MAOIs. Potentiates CNS depression with alcohol, other CNS depressants.
Drowsiness, dizziness, paradoxical excitement, anticholinergic effects, gastritis, hypotension, blood dyscrasias.
Formerly known under the brand name Periactin.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|